Cresskill, NJ: According to news reports, Pfizer has reached an undisclosed settlement in a lawsuit filed by Billy G. Bledsoe, Jr., who claimed Chantix caused him to have suicidal thoughts. The lawsuit was viewed as a bellwether case for other plaintiffs who have plans on pursuing litigation against the drug company. The settlement was offered to Bledsoe a week before the trial was scheduled to start. Ian Read, the CEO of Pfizer, was slated to testify at the trial. For plaintiff’s attorneys involved in Chantix litigation, RD Legal Funding can provide post-settlement financing once settlement amounts are determined.
It’s been well reported how hard it is to stop smoking. Products like Nicorette have hit the market place in hopes of catering to people who are looking for ways to quit. Chantix is another product designed for that purpose. Bloomberg reported in 2012 that there were more than 2,500 Chantix cases pending in federal court in Alabama. US District Judge Inge P. Johnson is presiding over the Chantix MDL.
The plaintiffs in the lawsuit allege Chantix has caused a number of severe side effects, many of which are psychological. Some of the reported side effects include a change in behavior, aggression, depression, suicidal thoughts, blackouts, heart attacks, and many others. Pfizer’s Chantix is a popular drug distributed in over 100 countries. Pfizer settled a lawsuit in late 2012 with the family of Mark Allan Whitely, who committed suicide while taking the drug. The terms of both the Whitley and Bledsoe settlements are confidential.
RD Legal Funding can provide plaintiff’s attorneys with Chantix settlements interim post-settlement funding, which provides immediate capital on unpaid legal fees. Settlement financing does not require any kind of payments until the fee is paid; there are no monthly interest or principal payments, no upfront points or fees. RD Legal Funding can wire funds within several days of receiving necessary documentation.
For more information on accelerating your legal fees, contact Joseph Genovesi at 1-800-565-5177, or fill out our brief online application.
